Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
ARUP Laboratories, |
RCV001001102 | SCV001158239 | uncertain significance | not specified | 2019-02-20 | criteria provided, single submitter | clinical testing | The HBA2: c.24G>T; p.Lys8Asn variant (also known as Lys7Asn when numbered from the mature protein, rs281860604), to our knowledge, is not reported in the medical literature or gene-specific databases. However, a variant causing the same amino acid substitution (Hb Tatras: c.24G>C; p.Lys8Asn) is reported in the literature in an asymptomatic heterozygous individual with a normal hematological profile (Wajcman 1994, HbVar database). The c.24G>T variant is absent from general population databases (Exome Variant Server, Genome Aggregation Database), indicating it is not a common polymorphism. The lysine at codon 8 is moderately conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is deleterious, although these predictions are low-confidence for the HBA2 gene. However, due to limited information, the clinical significance of the c.24G>T; p.Lys8Asn variant is uncertain at this time. References: HbVar link to HB Tatras: http://globin.bx.psu.edu/cgi-bin/hbvar/query_vars3?mode=output&display_format=page&i=10 Wajcman H et al. Two new alpha chain variants found during glycated hemoglobin screening: Hb Tatras [alpha 7(A5)Lys-->Asn] and HB Lisbon [alpha 23(B4)Glu-->Asp]. Hemoglobin. 1994 Nov;18(6):427-32. |
Natera, |
RCV001832318 | SCV002093838 | uncertain significance | alpha Thalassemia | 2021-02-09 | no assertion criteria provided | clinical testing |